The A-List: 2004's Trend-Shaping Series A Financings

Analyzing the venture financings closed by 2004's new crop of biotech, diagnostics, and medical device start-ups reveals today's trends that may shape tomorrow's health care industry. Here we point out eleven 2004 Series A financings that identify and illustrate what's hot.

The return of the health care IPO market in late 2003 certainly buoyed industry spirits, particularly in venture capital and entrepreneurial sectors, although VCs on the whole could be forgiven for not being ecstatic about the valuations their portfolio companies were grabbing. Initial public offerings continued throughout 2004, and while few companies of any stripe were able to pair outstanding valuations with solid post-float performances, as we have pointed out throughout the duration of the window in our Valuation Watch columns, in the end it mattered little to the overall scheme. Public money was returning to younger biotech and medical device firms in levels not seen in a few years. (See, for example, "IPO Step-Ups By Therapeutic Area: Is Your Disease Focus Hot or Not?" START-UP, December 2004 Also see "IPO Step-Ups By Therapeutic Area: Is Your Disease Focus Hot or Not?" - Scrip, 1 December, 2004..)

If it is helpful to analyze the appetites of public investors that determine the characteristics of the current crop of...

More from Strategy

More from Business

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By 

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?

Cipla CEO On Tariff Threat: ‘We Have One Of The Most Well Diversified Models’

 

Cipla's leadership fields shareholder queries on the specter of US tariffs and also outlines how the firm is nurturing the business for the future in areas like mRNA and point-of-care diagnostics, while building on its strength in the respiratory space.